Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Alkermes is a biopharmaceutical company focused on developing medicines for complex neurological and psychiatric disorders. The company employs its neuroscience expertise to create innovative treatment options.

msh id	COM:ALKERMES
symbol	ALKS
name	Alkermes plc
homepage url	https://www.alkermes.com
country	IE
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	2.1K
crunchbase url	-
linkedin url	-
founders	-

market cap	3.89B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0
growth cost of revenue	0.32
growth depreciation and amortization	0.57
growth ebitda	6.06
growth ebitda ratio	4.38
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.02
growth gross profit	0.54
growth gross profit ratio	0.03

COM:ALKERMES

Alkermes

Last Close

27.91

21/11 21:00

Market Cap

3.89B

Beta: -

Volume Today

1.83M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.25B
cost of revenue	1.25B
depreciation and amortization	72.61M
ebitda	486.73M
ebitda ratio	0.29
eps	2.14
eps diluted	2.1
operating expenses	960.56M
operating income	414.12M
operating income ratio	0.25

accounts receivables	-44.51M
capital expenditure	-48.05M
cash at beginning of period	292.47M
cash at end of period	457.47M
inventory	186.41M
working capital ttm	1.07B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-